Immunexpress is developing technology to accurately rule-in or rule-out sepsis in patients suspected of infection.

Lack of reliable diagnostics leads to the over-treatment of sepsis, creating an overwhelming burden to healthcare systems, hospitals, clinicians, nurses, payers and antibiotic stewardship efforts.

The goal is to transform sepsis diagnostics by providing clinicians with the technology to rapidly enable and confidently make the right treatment decisions.  

Immunexpress was founded in Australia in 2006 with the exclusive purpose of developing and commercializing SeptiCyte™ technology. Immunexpress is a privately-owned company with offices in Seattle, USA, and Brisbane, Australia. Immunexpress’ products are based on patented host immune response technologies validated in large human clinical trials around the globe.